lansoprazole has been researched along with Gastritis in 106 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Gastritis: Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Changes in gastric histology associated with long-term maintenance therapy with lansoprazole for erosive oesophagitis have not been well described." | 9.14 | Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2010) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 9.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 7.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| "A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole." | 7.69 | Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 7.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| "Normally, hiccups are treated without intervention." | 5.39 | The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report. ( Kamnasaran, D; Maximov, G, 2013) |
| "Helicobacter pylori causes chronic gastritis, gastroduodenal ulcers, and gastric cancer, and has been treated with two antibiotics (amoxicillin and clarithromycin) and proton-pump inhibitors (PPIs)." | 5.22 | The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial. ( Chun, J; Kim, BG; Kim, BS; Kim, JS; Kim, JW; Koh, SJ; Lee, KL; Oh, B, 2016) |
| " pylori infected gastritis patients were randomized to receive 7- or 14-day standard triple therapy plus bismuth with probiotic or placebo." | 5.19 | Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. ( Mahachai, V; Siramolpiwat, S; Srinarong, C; Vilaichone, RK; Wongcha-um, A, 2014) |
| "to assess the safety and effectiveness of lansoprazole injection (Prosogan®) in patients with upper gastrointestinal bleeding due to peptic ulcers or erosive gastritis." | 5.17 | Safety and efficacy of lansoprazole injection in upper gastrointestinal bleeding: a postmarketing surveillance conducted in Indonesia. ( Setiawati, A; Syam, AF, 2013) |
| "Changes in gastric histology associated with long-term maintenance therapy with lansoprazole for erosive oesophagitis have not been well described." | 5.14 | Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy. ( Atkinson, S; Freston, JW; Haber, MM; Hisada, M; Hunt, B; Kovacs, TO; Peura, DA, 2010) |
| "One hundred and eight patients with pangastritis were assigned to either lansoprazole 30 mg once a day (n=54) or bismuth 240 mg bis in die (n=54) for 14 days combined, for the first week, with amoxicillin 1g plus metronidazole 250 mg tris in die." | 5.14 | High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis. ( Abdullahi, M; Annibale, B; Capoccia, D; Leonetti, F; Marcheggiano, A; Osborn, J; Severi, C; Tari, R; Vannella, L, 2009) |
| "Ninety-one Helicobacter pylori-positive patients with nonulcer dyspepsia were randomized to receive either lansoprazole, amoxicillin, and clarithromycin or lansoprazole and placebo." | 5.12 | Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study. ( Barros, SG; Cartell, A; Edelweiss, MI; Francesconi, CF; Fritscher, LG; Mazzoleni, LE; Ott, EA; Polanczyk, CA; Prolla, JC; Rivero, LF; Sander, GB; Theil, AL; Uchôa, DM; Wortmann, AC, 2006) |
| " pylori-positive gastritis or peptic ulcers were randomly assigned to receive 30 mg lansoprazole twice daily (LAC group), 10 mg rabeprazole twice daily (RAC20 group), or 20 mg rabeprazole twice daily (RAC40 group), with 1000 mg amoxicillin twice daily and 400 mg clarithromycin twice daily for 1 week." | 5.10 | Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. ( Aoyama, N; Kasuga, M; Kita, T; Kuroda, K; Maekawa, S; Miki, I; Okumura, K; Sakaeda, T; Sakai, T; Shirasaka, D; Tamura, T; Wambura, CM, 2003) |
| " All patients belong to a low socioeconomic strata, had multifocal atrophic gastritis documented by gastric biopsies, and had been treated previously and unsuccessfully for 2 weeks with bismuth subsalicylate (262 mg four times a day), amoxicillin (500 mg three times a day), and metronidazole (400 mg three times a day)." | 5.09 | Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. ( Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL, 1999) |
| "Among the 15 patients with hemorrhagic acute gastritis who were randomly allocated to group A (eradication therapy) or group B (Lansoprazole, LPZ), 10 of them started to receive treatment within 1 day after the disease onset." | 5.09 | A short-term eradication therapy for Helicobacter pylori acute gastritis. ( Asaka, M; Kashiwagi, S; Miyake, K; Nomura, H; Sugiyama, T, 2000) |
| "Satisfactory antral biopsies were obtained from 119 duodenal ulcer patients before and after 4 wk of therapy with lansoprazole, ranitidine, or placebo." | 5.08 | The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients. ( Atkinson, BF; Brightman, SA; Jhala, NC; McFarland, MM; Morale, B; Rubin, W, 1995) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| " pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients." | 5.08 | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. ( Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A, 1997) |
| " pylori-infected duodenal ulcer patients we investigated the gastritis parameters in antral and corpus mucosa before treatment, after 6 and 12 months of therapy, and 6 months after termination of treatment with 15 mg lansoprazole or 150 mg ranitidine/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease. ( Kiel, G; Meining, A; Stolte, M, 1998) |
| " pylori-associated gastritis, received seven days of lansoprazole, bismuth, tetracycline and metronidazole after three days of lansoprazole pretreatment." | 5.08 | Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. ( Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB, 1998) |
| " pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone." | 5.08 | Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996) |
| " In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole." | 4.78 | Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993) |
| "In 2008, a 44-year-old woman with mild epigastralgia diagnosed as having Helicobacter pylori-positive chronic gastritis without peptic ulcer underwent eradication therapy with lansoprazole (LPZ), amoxicillin (AMPC) and clarithromycin (CAM) for 7 days, but it failed, so treatment with rabeprazole, AMPC, and metronidazole (MNZ) for another 7 days was given, but it also failed." | 3.78 | Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy. ( Inoue, H; Inoue, T; Maruoka, Y; Nakajima, S, 2012) |
| " pylori-negative subjects with erosive esophagitis (>or= grade 2; n=196), nonerosive reflux disease (n=688), or functional dyspepsia (n=711) who participated in US Takeda-sponsored lansoprazole trials." | 3.76 | Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. ( Atkinson, S; Haber, MM; Hunt, B; Peura, DA, 2010) |
| " Helicobacter pylori-infected patients with gastritis and gastric ulcer received eradication therapy: lansoprazole (60 mg/day), clarithromycin (400 mg/day), and amoxicillin (1500 mg/day) for 1 week." | 3.74 | Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura. ( Arakawa, Y; Hatta, Y; Hayashi, I; Iwamoto, M; Kato, K; Kurihara, R; Kurosaka, H; Matsukawa, Y; Mizuno, S; Sawada, S, 2007) |
| "Biopsy specimens were taken from the duodenal ulcer patients who underwent gastroscopy before and after the treatment of Lansoprazole." | 3.73 | [Distribution of Helicobacter pylori in stomach before and after the administration of Lansoprazole]. ( Cheng, HY; Dong, XY; Jin, Z; Lin, SR; Ye, SM; Zhou, LY, 2005) |
| " pylori infection who had gastritis, duodenal ulcer (DU) or gastric ulcer (GU) received 1 week's triple therapy of lansoprazole 30 g once daily (OD), amoxycillin 250 mg qid and clarithromycin 250 mg tid." | 3.72 | Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection. ( Uthaisaengsook, W, 2003) |
| " pylori infection on gastritis, enterochromaffin-like cell density and hyperplasia, mucosal atrophy and serum gastrin in patients with gastric hypersecretion (basal acid output gt; 15 mmol/h) with either hypergastrinemia (Zollinger-Ellison syndrome) or normal gastrin (non-Zollinger-Ellison syndrome) before and during long-term treatment with lansoprazole." | 3.71 | Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole. ( Haber, MM; Hirschowitz, BI, 2001) |
| "Thirty-eight clinical strains of Helicobacter pylori were isolated from patients with chronic gastritis and gastroduodenal ulceration, and their susceptibility to macrolide antibiotics (roxithromycin, flurithromycin, azithromycin, erythromycin) in combination with proton-pump inhibitors (lansoprazole and omeprazole) and bismuth subcitrate was assayed." | 3.70 | Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study. ( Campa, M; Favini, P; Malizia, T; Marchetti, F; Pizzarelli, G; Senesi, S; Tejada, M, 1998) |
| "Gastric juice pH, ammonia concentration in gastric juice, serum gastrin level, and grade of gastritis in accordance with the Sydney System were determined for patients with gastric ulcer (GU) and duodenal ulcer (DU) before and after treatment with lansoprazole and amoxicillin, and results were compared with those of H." | 3.70 | Effect of Helicobacter pylori infection on gastric juice pH. ( Arai, H; Baba, S; Furuta, T; Futami, H; Hanai, H; Kajimura, M; Kaneko, E; Takashima, M, 1998) |
| " Given the histology and the fact that rapid urease test results were positive, chronic active gastritis with H." | 3.70 | Iron-deficiency anemia associated with Helicobacter pylori gastritis. ( Imai, T; Konno, M; Muraoka, S; Takahashi, M, 2000) |
| "A marked increase in body gastritis was observed in H pylori infected individuals during long term treatment with the proton pump inhibitor lansoprazole." | 3.69 | Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. ( Berstad, A; Berstad, AE; Brandtzaeg, P; Hatlebakk, JG; Maartmann-Moe, H, 1997) |
| " pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole." | 3.69 | Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. ( Arnold, R; Brunner, G; Eissele, R; Simon, B; Solcia, E, 1997) |
| "The most common adverse event was the dysgeusia in both the groups." | 2.87 | Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial. ( Shahbazi, S; Vahdat Shariatpanahi, Z, 2018) |
| " The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28." | 2.82 | Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study. ( Benedeto-Stojanov, D; Grgov, S; Radovanović-Dinić, B; Tasić, T, 2016) |
| " Sixty-eight patients received 30 mg of lansoprazole once daily, 500 mg of amoxicillin and 250 mg of metronidazole thrice daily for 2 weeks (LAM group), while the other 67 patients received the same dosage of those agents plus 18,000 tyrosine units of pronase thrice daily for 2 weeks (LAMP group)." | 2.70 | Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. ( Akamatsu, T; Gotoh, A; Ikeno, T; Ishida, K; Kaneko, T; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Ota, H; Shimizu, T; Shimodaira, K; Sugiyama, A, 2002) |
| "The 1-week triple therapy was safe and effective for eradicating H." | 2.69 | Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children. ( Asaka, M; Iinuma, K; Kato, S; Ohnuma, K; Ritsuno, H; Sugiyama, T, 1998) |
| " The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ)." | 2.69 | Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. ( Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J, 1999) |
| "pylori associated diseases such as gastric cancer is expected." | 2.50 | [Expanded indication of National Health Insurance for H. pylori associated gastritis]. ( Kato, M, 2014) |
| "Gastric MALT lymphomas are endoscopically classified into three common types: superficial, ulcerative, and elevated types." | 1.51 | Helicobacter suis infection is associated with nodular gastritis-like appearance of gastric mucosa-associated lymphoid tissue lymphoma. ( Chayama, K; Kitadai, Y; Masaki, S; Matsuo, K; Matsuo, T; Naito, T; Sentani, K; Takigawa, H; Tanaka, S; Urabe, Y; Yuge, R, 2019) |
| " Examination of eradication rates according to CAM dosage revealed an eradication rate of 65." | 1.40 | Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). ( Asaoka, D; Ito, M; Kawai, T; Kawakami, K; Kurihara, N; Masaoaka, T; Matsuhisa, T; Mine, T; Mizuno, S; Nagahara, A; Nishizawa, T; Ohkusa, T; Omata, F; Sakaki, N; Sasaki, H; Suzuki, H; Suzuki, M; Takahashi, S; Tokunaga, K; Torii, A, 2014) |
| "Normally, hiccups are treated without intervention." | 1.39 | The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report. ( Kamnasaran, D; Maximov, G, 2013) |
| "In two patients with MALT lymphoma, H." | 1.33 | Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients. ( Akamatsu, T; Hidaka, E; Matsuzawa, K; Okiyama, Y; Ota, H; Sano, K, 2005) |
| " pylori-infected mucosa and that inhibited the loss of CAM bioavailability in the acidic environment." | 1.32 | Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice. ( Fujioka, T; Kashimura, K; Kodama, M; Miura, M; Miyajima, H; Murakami, K; Nasu, M; Okimoto, T; Ootsu, S; Sato, R; Watanabe, K, 2004) |
| "Gastric metaplasia was endoscopically and histologically evaluated before and after eradication of this bacterium." | 1.32 | Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. ( Sano, T; Urakami, Y, 2003) |
| "Hypogonadism has been established as a cause of osteoporosis in males, and in this case would explain the occurrence of fractures in the absence of other major risk factors." | 1.31 | Osteoporosis with underlying connective tissue disease: an unusual case. ( De Silva, M; Prasad, R, 2002) |
| "Lactoferrin (Lf) is an iron-binding glycoprotein present in milk, lacrimae, saliva, and gastroduodenal secretions." | 1.30 | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. ( Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N, 1997) |
| "Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55." | 1.30 | A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 33 (31.13) | 18.2507 |
| 2000's | 51 (48.11) | 29.6817 |
| 2010's | 21 (19.81) | 24.3611 |
| 2020's | 1 (0.94) | 2.80 |
| Authors | Studies |
|---|---|
| Páramo-Zunzunegui, J | 1 |
| Ortega-Fernandez, I | 1 |
| Benito-Barbero, S | 1 |
| Rubio-López, L | 1 |
| Grgov, S | 1 |
| Tasić, T | 1 |
| Radovanović-Dinić, B | 1 |
| Benedeto-Stojanov, D | 1 |
| Auesomwang, C | 1 |
| Maneerattanaporn, M | 1 |
| Chey, WD | 1 |
| Kiratisin, P | 1 |
| Leelakusolwong, S | 1 |
| Tanwandee, T | 1 |
| Sue, S | 1 |
| Shibata, W | 1 |
| Sasaki, T | 1 |
| Kaneko, H | 1 |
| Irie, K | 1 |
| Kondo, M | 1 |
| Maeda, S | 1 |
| Shahbazi, S | 1 |
| Vahdat Shariatpanahi, Z | 1 |
| Takigawa, H | 1 |
| Masaki, S | 1 |
| Naito, T | 1 |
| Yuge, R | 1 |
| Urabe, Y | 1 |
| Tanaka, S | 2 |
| Sentani, K | 1 |
| Matsuo, T | 1 |
| Matsuo, K | 1 |
| Chayama, K | 2 |
| Kitadai, Y | 1 |
| Sierra, F | 1 |
| Forero, JD | 1 |
| Rey, M | 1 |
| Botero, ML | 1 |
| Cárdenas, A | 1 |
| Syam, AF | 1 |
| Setiawati, A | 1 |
| Maximov, G | 1 |
| Kamnasaran, D | 1 |
| Pierog, AA | 1 |
| Mencin, AA | 1 |
| Settin, A | 1 |
| Abdalla, AF | 1 |
| Al-Hussaini, AS | 1 |
| El-Baz, R | 1 |
| Galal, A | 1 |
| Kato, M | 2 |
| Srinarong, C | 1 |
| Siramolpiwat, S | 1 |
| Wongcha-um, A | 1 |
| Mahachai, V | 1 |
| Vilaichone, RK | 1 |
| Kawai, T | 1 |
| Takahashi, S | 2 |
| Suzuki, H | 4 |
| Sasaki, H | 1 |
| Nagahara, A | 1 |
| Asaoka, D | 1 |
| Matsuhisa, T | 1 |
| Masaoaka, T | 1 |
| Nishizawa, T | 1 |
| Suzuki, M | 3 |
| Ito, M | 3 |
| Kurihara, N | 1 |
| Omata, F | 1 |
| Mizuno, S | 2 |
| Torii, A | 1 |
| Kawakami, K | 1 |
| Ohkusa, T | 1 |
| Tokunaga, K | 1 |
| Mine, T | 1 |
| Sakaki, N | 1 |
| Oh, B | 1 |
| Kim, BS | 1 |
| Kim, JW | 1 |
| Kim, JS | 1 |
| Koh, SJ | 1 |
| Kim, BG | 1 |
| Lee, KL | 1 |
| Chun, J | 1 |
| Todo, K | 1 |
| Ohmae, T | 1 |
| Osamura, T | 1 |
| Imamura, T | 1 |
| Imashuku, S | 1 |
| Okamoto, K | 1 |
| Isomoto, H | 2 |
| Shikuwa, S | 1 |
| Nishiyama, H | 1 |
| Kohno, S | 2 |
| Severi, C | 2 |
| Abdullahi, M | 1 |
| Tari, R | 1 |
| Vannella, L | 2 |
| Marcheggiano, A | 2 |
| Capoccia, D | 1 |
| Leonetti, F | 1 |
| Osborn, J | 1 |
| Annibale, B | 3 |
| Peura, DA | 2 |
| Haber, MM | 3 |
| Hunt, B | 2 |
| Atkinson, S | 2 |
| Freston, JW | 1 |
| Kovacs, TO | 1 |
| Hisada, M | 1 |
| Okubo, M | 1 |
| Tahara, T | 1 |
| Shibata, T | 2 |
| Nakamura, M | 1 |
| Yoshioka, D | 1 |
| Maeda, Y | 1 |
| Yonemura, J | 1 |
| Ishizuka, T | 1 |
| Arisawa, T | 1 |
| Hirata, I | 1 |
| Zullo, A | 1 |
| Hassan, C | 1 |
| Sbrozzi-Vanni, A | 1 |
| Huang, YK | 1 |
| Wu, MC | 1 |
| Wang, SS | 1 |
| Kuo, CH | 1 |
| Lee, YC | 1 |
| Chang, LL | 1 |
| Wang, TH | 1 |
| Chen, YH | 1 |
| Wang, WM | 1 |
| Wu, DC | 1 |
| Kuo, FC | 1 |
| Nakajima, S | 1 |
| Inoue, H | 1 |
| Inoue, T | 1 |
| Maruoka, Y | 1 |
| Prasad, R | 1 |
| De Silva, M | 1 |
| Murakami, K | 4 |
| Sato, R | 3 |
| Okimoto, T | 3 |
| Nasu, M | 3 |
| Fujioka, T | 4 |
| Kodama, M | 3 |
| Kagawa, J | 1 |
| Sato, S | 1 |
| Abe, H | 1 |
| Arita, T | 1 |
| Kawano, S | 1 |
| Miki, I | 1 |
| Aoyama, N | 2 |
| Sakai, T | 1 |
| Shirasaka, D | 2 |
| Wambura, CM | 1 |
| Maekawa, S | 2 |
| Kuroda, K | 2 |
| Tamura, T | 2 |
| Kita, T | 1 |
| Sakaeda, T | 1 |
| Okumura, K | 1 |
| Kasuga, M | 2 |
| Urakami, Y | 1 |
| Sano, T | 1 |
| Miyamoto, M | 1 |
| Haruma, K | 1 |
| Yoshihara, M | 1 |
| Sumioka, M | 1 |
| Kamada, T | 1 |
| Masuda, H | 1 |
| Nishisaka, T | 1 |
| Uthaisaengsook, W | 1 |
| Furuta, T | 3 |
| Shirai, N | 2 |
| Xiao, F | 1 |
| El-Omar, EM | 1 |
| Rabkin, CS | 1 |
| Sugimura, H | 1 |
| Ishizaki, T | 2 |
| Ohashi, K | 2 |
| Asaumi, N | 1 |
| Niiya, K | 1 |
| Yoshida, C | 1 |
| Shibakura, M | 1 |
| Niiya, M | 1 |
| Tanimoto, M | 1 |
| Tiesmeier, J | 1 |
| Hinner, H | 1 |
| Kraus, J | 1 |
| Schuppert, F | 1 |
| Oderda, G | 1 |
| Marinello, D | 1 |
| Lerro, P | 1 |
| Kuvidi, M | 1 |
| de'Angelis, GL | 1 |
| Ferzetti, A | 1 |
| Cucchiara, S | 1 |
| Franco, MT | 1 |
| Romano, C | 1 |
| Strisciuglio, P | 1 |
| Pensabene, L | 1 |
| Masaoka, T | 1 |
| SuzukiKurabayashi, HK | 1 |
| Kamiya, AG | 1 |
| Ishii, H | 3 |
| Kondo, Y | 1 |
| Joh, T | 1 |
| Sasaki, M | 1 |
| Oshima, T | 1 |
| Itoh, K | 1 |
| Tanida, S | 1 |
| Kataoka, H | 1 |
| Ohara, H | 1 |
| Nomura, T | 1 |
| Itoh, M | 1 |
| Wambura, C | 1 |
| Ebara, S | 1 |
| Watanabe, Y | 1 |
| Watanabe, K | 2 |
| Kashimura, K | 1 |
| Miura, M | 1 |
| Ootsu, S | 1 |
| Miyajima, H | 1 |
| Arkkila, PE | 1 |
| Seppälä, K | 1 |
| Kosunen, TU | 1 |
| Sipponen, P | 1 |
| Mäkinen, J | 1 |
| Rautelin, H | 1 |
| Färkkilä, M | 1 |
| Mana, F | 1 |
| Van Laer, W | 1 |
| Van Laere, W | 1 |
| Bossuyt, A | 1 |
| Urbain, D | 1 |
| Chang, CC | 1 |
| Chen, SH | 1 |
| Lien, GS | 1 |
| Lee, YJ | 1 |
| Lou, HY | 1 |
| Hsieh, CR | 1 |
| Fang, CL | 1 |
| Pan, S | 1 |
| Marusic, M | 1 |
| Babic, Z | 1 |
| Nesanovic, M | 1 |
| Lucijanic-Mlinac, M | 1 |
| Stajcar, V | 1 |
| Jin, Z | 1 |
| Dong, XY | 1 |
| Lin, SR | 1 |
| Ye, SM | 1 |
| Zhou, LY | 1 |
| Cheng, HY | 1 |
| Sagehashi, Y | 1 |
| Sugimoto, M | 1 |
| Nakamura, A | 1 |
| Kodaira, M | 1 |
| Kenmotsu, K | 1 |
| Nagano, M | 1 |
| Egashira, T | 1 |
| Ueda, K | 1 |
| Yoneyama, M | 1 |
| Hishida, A | 1 |
| Okiyama, Y | 1 |
| Matsuzawa, K | 1 |
| Hidaka, E | 1 |
| Sano, K | 1 |
| Akamatsu, T | 2 |
| Ota, H | 2 |
| Kim, SS | 1 |
| Meitner, P | 1 |
| Konkin, TA | 1 |
| Cho, YS | 1 |
| Resnick, MB | 1 |
| Moss, SF | 1 |
| Magalhães, AF | 1 |
| Carvalhaes, A | 1 |
| Natan-Eisig, J | 1 |
| Paraíso-Ferraz, JG | 1 |
| Trevisan, M | 1 |
| Zaterkaad, S | 1 |
| Mazzoleni, LE | 1 |
| Sander, GB | 1 |
| Ott, EA | 1 |
| Barros, SG | 1 |
| Francesconi, CF | 1 |
| Polanczyk, CA | 1 |
| Wortmann, AC | 1 |
| Theil, AL | 1 |
| Fritscher, LG | 1 |
| Rivero, LF | 1 |
| Cartell, A | 1 |
| Edelweiss, MI | 1 |
| Uchôa, DM | 1 |
| Prolla, JC | 1 |
| Matsukawa, Y | 1 |
| Kato, K | 1 |
| Hatta, Y | 1 |
| Iwamoto, M | 1 |
| Kurihara, R | 1 |
| Arakawa, Y | 1 |
| Kurosaka, H | 1 |
| Hayashi, I | 1 |
| Sawada, S | 1 |
| Cindoruk, M | 1 |
| Yetkin, I | 1 |
| Deger, SM | 1 |
| Karakan, T | 1 |
| Kan, E | 1 |
| Unal, S | 1 |
| Serebrova, SIu | 1 |
| Chen, ZM | 1 |
| Shah, R | 1 |
| Zuckerman, GR | 1 |
| Wang, HL | 1 |
| Chen, MJ | 1 |
| Shih, SC | 1 |
| Wang, TE | 1 |
| Chan, YJ | 1 |
| Chen, CJ | 1 |
| Chang, WH | 1 |
| Romero-Gallo, J | 1 |
| Harris, EJ | 1 |
| Krishna, U | 1 |
| Washington, MK | 1 |
| Perez-Perez, GI | 1 |
| Peek, RM | 1 |
| Watari, J | 1 |
| Das, KK | 1 |
| Amenta, PS | 1 |
| Tanabe, H | 1 |
| Tanaka, A | 1 |
| Geng, X | 1 |
| Lin, JJ | 1 |
| Kohgo, Y | 1 |
| Das, KM | 1 |
| Bender, E | 1 |
| Schmidt, SP | 1 |
| Jhala, NC | 1 |
| McFarland, MM | 1 |
| Brightman, SA | 1 |
| Morale, B | 1 |
| Rubin, W | 1 |
| Atkinson, BF | 1 |
| Cahill, RJ | 1 |
| Xia, H | 1 |
| Kilgallen, C | 1 |
| Beattie, S | 1 |
| Hamilton, H | 1 |
| O'Morain, C | 2 |
| Ozmen, MM | 1 |
| Johnson, CD | 1 |
| Choné, L | 1 |
| Fléjou, JF | 1 |
| Grignon, Y | 1 |
| Bigard, MA | 1 |
| Florent, C | 1 |
| Pallone, F | 1 |
| Luzza, F | 1 |
| Delle Fave, G | 1 |
| Biancone, L | 1 |
| Torsoli, A | 1 |
| Capurso, L | 1 |
| Stermer, E | 1 |
| Levy, N | 1 |
| Gough, AL | 1 |
| Long, RG | 1 |
| Cooper, BT | 2 |
| Fosters, CS | 1 |
| Garrett, AD | 1 |
| Langworthy, CH | 1 |
| Nishizono, A | 1 |
| Nagai, J | 1 |
| Tokieda, M | 1 |
| Kodama, R | 1 |
| Kubota, T | 1 |
| Bock, H | 1 |
| Mares, A | 1 |
| Wang, XM | 1 |
| Taniguchi, Y | 1 |
| Nishifuku, K | 1 |
| Kidaira, K | 1 |
| Sato, K | 1 |
| Sohara, H | 1 |
| Kawada, H | 1 |
| Kimura, K | 1 |
| Kajiwara, M | 1 |
| Caselli, M | 1 |
| Trevisani, L | 1 |
| Tursi, A | 1 |
| Sartori, S | 1 |
| Ruina, M | 1 |
| Luzzi, I | 1 |
| Gaudenzi, P | 1 |
| Alvisi, V | 1 |
| Gasbarrini, G | 1 |
| Eissele, R | 1 |
| Brunner, G | 1 |
| Simon, B | 1 |
| Solcia, E | 1 |
| Arnold, R | 1 |
| Nakao, K | 1 |
| Imoto, I | 1 |
| Ikemura, N | 1 |
| Takaji, S | 1 |
| Taguchi, Y | 1 |
| Misaki, M | 1 |
| Yamauchi, K | 1 |
| Yamazaki, N | 1 |
| Hirakawa, T | 1 |
| Leufkens, H | 1 |
| Claessens, A | 1 |
| Heerdink, E | 1 |
| van Eijk, J | 1 |
| Lamers, CB | 1 |
| Harford, W | 1 |
| Lanza, F | 1 |
| Arora, A | 1 |
| Graham, D | 1 |
| Haber, M | 1 |
| Weissfeld, A | 1 |
| Rose, P | 1 |
| Siepman, N | 1 |
| Mégraud, F | 1 |
| Malfertheiner, P | 2 |
| Misiewicz, JJ | 1 |
| Harris, AW | 1 |
| Bardhan, KD | 1 |
| Levi, S | 1 |
| Kerr, GD | 1 |
| Dixon, MF | 1 |
| Langworthy, H | 1 |
| Piper, D | 1 |
| Berstad, AE | 1 |
| Hatlebakk, JG | 1 |
| Maartmann-Moe, H | 1 |
| Berstad, A | 1 |
| Brandtzaeg, P | 1 |
| Stolte, M | 2 |
| Meining, A | 2 |
| Schmitz, JM | 1 |
| Alexandridis, T | 1 |
| Seifert, E | 1 |
| Malizia, T | 1 |
| Tejada, M | 1 |
| Marchetti, F | 1 |
| Favini, P | 1 |
| Pizzarelli, G | 1 |
| Campa, M | 1 |
| Senesi, S | 1 |
| Baba, S | 1 |
| Takashima, M | 1 |
| Futami, H | 1 |
| Arai, H | 1 |
| Kajimura, M | 1 |
| Hanai, H | 1 |
| Kaneko, E | 1 |
| Mori, M | 1 |
| Sakaguchi, AA | 1 |
| Miura, S | 1 |
| Kiel, G | 1 |
| Korman, MG | 1 |
| Bolin, TD | 1 |
| Nicholson, FB | 1 |
| Engelman, JL | 1 |
| Kato, S | 1 |
| Ritsuno, H | 1 |
| Ohnuma, K | 1 |
| Iinuma, K | 1 |
| Sugiyama, T | 3 |
| Asaka, M | 3 |
| Dattilo, M | 1 |
| Figura, N | 1 |
| Pilotto, A | 1 |
| Franceschi, M | 1 |
| Leandro, G | 1 |
| Bozzola, L | 1 |
| Fortunato, A | 1 |
| Rassu, M | 1 |
| Meli, S | 1 |
| Soffiati, G | 1 |
| Scagnelli, M | 1 |
| Di Mario, F | 1 |
| Valerio, G | 1 |
| Lombardo, L | 1 |
| Masoero, G | 1 |
| Della Monica, P | 1 |
| Pera, A | 1 |
| Mera, R | 1 |
| Realpe, JL | 1 |
| Bravo, LE | 1 |
| DeLany, JP | 1 |
| Correa, P | 1 |
| Feldman, M | 1 |
| Cryer, B | 1 |
| Sammer, D | 1 |
| Lee, E | 1 |
| Spechler, SJ | 1 |
| Nishikawa, K | 1 |
| Ishizuka, J | 1 |
| Kudo, T | 1 |
| Komatsu, Y | 1 |
| Katagiri, M | 1 |
| Sukegawa, M | 1 |
| Kagaya, H | 1 |
| Kudo, M | 1 |
| Takeda, H | 1 |
| Toyota, J | 1 |
| Shashidhar, H | 1 |
| Peters, J | 1 |
| Lin, CH | 1 |
| Rabah, R | 1 |
| Thomas, R | 1 |
| Tolia, V | 1 |
| Konno, M | 1 |
| Muraoka, S | 1 |
| Takahashi, M | 1 |
| Imai, T | 1 |
| Giannini, E | 1 |
| Romagnoli, P | 1 |
| Fasoli, A | 1 |
| Chiarbonello, B | 1 |
| Malfatti, F | 1 |
| Botta, F | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Savarino, V | 1 |
| Testa, R | 1 |
| Hirschowitz, BI | 1 |
| Nomura, H | 1 |
| Miyake, K | 1 |
| Kashiwagi, S | 1 |
| Toyoda, H | 1 |
| Yamaguchi, M | 1 |
| Nakamura, S | 1 |
| Nakamura, T | 1 |
| Kimura, M | 1 |
| Mukai, K | 1 |
| Sawa, H | 1 |
| Kawamura, K | 1 |
| Shiku, H | 1 |
| Grigor'ev, PIa | 1 |
| Iakovenko, EP | 1 |
| Talanova, EV | 1 |
| Geboes, K | 1 |
| Dekker, W | 1 |
| Mulder, CJ | 1 |
| Nusteling, K | 1 |
| Treiber, G | 1 |
| Wittig, J | 1 |
| Ammon, S | 1 |
| Walker, S | 1 |
| van Doorn, LJ | 1 |
| Klotz, U | 1 |
| Koçkar, C | 1 |
| Oztürk, M | 1 |
| Bavbek, N | 1 |
| Kitahora, T | 1 |
| Miyazawa, M | 1 |
| Nagahashi, S | 1 |
| Suzuki, K | 1 |
| Gotoh, A | 1 |
| Shimizu, T | 1 |
| Shimodaira, K | 1 |
| Kaneko, T | 1 |
| Kiyosawa, K | 1 |
| Ishida, K | 1 |
| Ikeno, T | 1 |
| Sugiyama, A | 1 |
| Kawakami, Y | 1 |
| Katsuyama, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients[NCT01888237] | Phase 4 | 118 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection[NCT02711176] | Phase 4 | 212 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412] | Phase 4 | 330 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Dyspeptic Symptoms Evolution After Eradication of Helicobacter Pylori in Patients With Different Endoscopic Findings: a Randomized Double-blind Placebo-controlled Clinical Trial With 12 Months of Follow-up[NCT00404534] | Phase 3 | 407 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 49 |
| (2) Hybrid Regimen | 58 |
| (3) Levofloxacin Quadruple Regimen | 44 |
Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 102 |
| (2) Hybrid Regimen | 101 |
| (3) Levofloxacin Quadruple Regimen | 91 |
Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 109 |
| (2) Hybrid Regimen | 107 |
| (3) Levofloxacin Quadruple Regimen | 108 |
7 reviews available for lansoprazole and Gastritis
| Article | Year |
|---|---|
[Expanded indication of National Health Insurance for H. pylori associated gastritis].
Topics: Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Gast | 2014 |
[Helicobacter pylori induced gastritis: recent topics on eradication therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combinati | 2002 |
[The treatment of Helicobacter pylori infection in upper gastrointestinal disorders].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Gastritis; Gastrointes | 2003 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag | 1993 |
[Diagnosis and treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bacteriological Techniques; Clarithromycin; Dr | 1997 |
Helicobacter pylori infection, chronic gastritis, and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1998 |
[Helicobacter heilmannii-associated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combina | 2002 |
44 trials available for lansoprazole and Gastritis
| Article | Year |
|---|---|
Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Biopsy; Chronic Disease; Clarith | 2016 |
Ten-day high-dose proton pump inhibitor triple therapy versus sequential therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dizziness; Drug Therapy, Combinatio | 2018 |
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; F | 2019 |
Comparison between daily single-dose triple therapy and conventional triple therapy on patient compliance and Helicobacter pylori eradication: A randomized controlled trial.
Topics: Adult; Amoxicillin; Clarithromycin; Dysgeusia; Esomeprazole; Female; Gastritis; Helicobacter Infecti | 2018 |
Safety and efficacy of lansoprazole injection in upper gastrointestinal bleeding: a postmarketing surveillance conducted in Indonesia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Drug | 2013 |
Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Foll | 2014 |
The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; DNA, Ribosomal; Drug Therapy, Combination; Femal | 2016 |
High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2009 |
Changes of gastric histology in patients with erosive oesophagitis receiving long-term lansoprazole maintenance therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Double-Blind Meth | 2010 |
Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2012 |
Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2004 |
Dual vs. triple therapy for childhood Helicobacter pylori gastritis: a double-blind randomized multicentre trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Breath Tests; Child; Double-Blind | 2004 |
Helicobacter pylori eradication decreases blood neutrophil and monocyte counts.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Gastritis; | 2004 |
Helicobacter pylori eradication as the sole treatment for gastric and duodenal ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agent | 2005 |
Influence of various proton pump inhibitors on intestinal metaplasia in noneradicated Helicobacter pylori patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Benzimidazoles; | 2005 |
Clinical outcomes of eradication of Helicobacter pylori in nonulcer dyspepsia in a population with a high prevalence of infection: results of a 12-month randomized, double blind, placebo-controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2006 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
The effects of short-term lansoprazole therapy on Helicobacter pylori infection and antral gastritis in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Double-B | 1995 |
Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Clarithromyc | 1995 |
Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinatio | 1995 |
Lansoprazole and Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; | 1993 |
Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Diarrhea; Double-Blind Method; Enzyme Inhibitors; Esophagit | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; A | 1997 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar | 1996 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double | 1998 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during and after 12 months of treatment with ranitidine and lansoprazole in patients with duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gas | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Safety and efficacy of one-week triple therapy for eradicating Helicobacter pylori in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial | 1999 |
Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and azithromycin: failure of a "promising" association.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Do | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; C | 1999 |
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
A prospective trial of lansoprazole triple therapy for pediatric Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biop | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
A short-term eradication therapy for Helicobacter pylori acute gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Adolescent; Adult; Alanine; Amoxicillin; Ant | 2000 |
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhib | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Helicobacter pylori eradication with beta carotene, ascorbic acid and allicin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
Treatment with a proton pump inhibitor promotes corpus gastritis in patients with Helicobacter pylori-infected antrum-predominant gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Benzimidazoles; Biopsy; | 2002 |
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2002 |
55 other studies available for lansoprazole and Gastritis
| Article | Year |
|---|---|
Eosinophilic colitis: an infrequent disease with difficult diagnose.
Topics: Aged, 80 and over; Biopsy; Colitis; Colon; Colonoscopy; Cromolyn Sodium; Drug Therapy, Combination; | 2020 |
Helicobacter suis infection is associated with nodular gastritis-like appearance of gastric mucosa-associated lymphoid tissue lymphoma.
Topics: Adult; Amoxicillin; Clarithromycin; DNA, Bacterial; Drug Therapy, Combination; Gastritis; Helicobact | 2019 |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastri | 2013 |
The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report.
Topics: Aged; Clonazepam; Dimenhydrinate; Esophagitis, Peptic; Gastritis; Hiccup; Humans; Lansoprazole; Male | 2013 |
A childhood case of eosinophilic gastritis and protein-losing enteropathy.
Topics: Anti-Asthmatic Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Asthma; Child, Preschool; Cromol | 2014 |
Cure rate of Helicobacter pylori infection in Egyptian children related to CYP2C19 gene polymorphism.
Topics: Amoxicillin; Child; Clarithromycin; Cytochrome P-450 CYP2C19; Female; Gastritis; Helicobacter Infect | 2014 |
Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).
Topics: Amoxicillin; Chronic Disease; Clarithromycin; Disease Eradication; Female; Gastritis; Helicobacter I | 2014 |
Severe Helicobacter pylori gastritis-related thrombocytopenia and iron deficiency anemia in an adolescent female.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Breath Tests; Clarithromycin; Female; Gastritis; H | 2016 |
A case of Cronkhite-Canada syndrome: remission after treatment with anti-Helicobacter pylori regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alopecia; Amoxicillin; Anti-Bacterial Agents; Anti-Ul | 2008 |
Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2010 |
Changes in gastric mucosal patterns seen by magnifying NBI during H. pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2011 |
Role of gastritis pattern on Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2012 |
Multiple-antibiotic-resistant Helicobacter pylori infection eradicated with a tailor-made quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Aryl H | 2012 |
Osteoporosis with underlying connective tissue disease: an unusual case.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Accidental Falls; Adult; Anti-Ulcer Agents; Antibodies, Ant | 2002 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug The | 2003 |
Isolated granulomatous gastritis successfully treated by Helicobacter pylori eradication: a possible association between granulomatous gastritis and Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2003 |
Low dose, one-week triple therapy (lanzoprazole, amoxycillin, clarithromycin) for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Com | 2003 |
Complete remission of cyclic thrombocytopenia after Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; D | 2004 |
[Chronic upper abdominal pain without improvement after using proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Ulcer Agents; Azathioprine; Duodenal U | 2004 |
Second-line treatment of Helicobacter pylori infection after dilution agar methods and PCR-RFLP analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Clarithromycin; Colony Count, Mic | 2004 |
Influence of gastritis on cyclooxygenase-2 expression before and after eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cyclooxygenase 2; Female; Follow-Up Studies; G | 2004 |
Effect of sucralfate on antibiotic therapy for Helicobacter pylori infection in mice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2004 |
The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Breath Tests; Carbon Isotopes; Enzyme Inhibitors; Fem | 2005 |
Anti-Helicobacter pylori therapy significantly reduces Helicobacter pylori -induced gastric mucosal damage in Mongolian gerbils.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Age | 2005 |
[Distribution of Helicobacter pylori in stomach before and after the administration of Lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastric Mucosa; Gastriti | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2005 |
Helicobacter heilmannii infection: clinical, endoscopic and histopathological features in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithrom | 2005 |
Altered expression of Skp2, c-Myc and p27 proteins but not mRNA after H. pylori eradication in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
CagA status and Helicobacter pylori eradication among dyspeptic patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2005 |
Helicobacter pylori eradication reduces platelet count in patients without idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2007 |
Influence of H pylori on plasma ghrelin in patients without atrophic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2007 |
[The clinical effectiveness of rabeprazole in patients with acid-related gastric and duodenal diseases with various sensitivity of different types of parietal gastric cell receptors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastric Acid; Gastric Aci | 2007 |
Epstein-Barr virus gastritis: an underrecognized form of severe gastritis simulating gastric lymphoma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Diagnosis, Differential; Endoscopy, | 2007 |
Endoscopic patterns and histopathological features after eradication therapy in Helicobacter pylori-associated nodular gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alkylating Agents; Amoxicillin; Anti-Bacterial Agent | 2008 |
Effect of Helicobacter pylori eradication on gastric carcinogenesis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Amoxicillin; Animals; Animals, Outbred Stra | 2008 |
Effect of eradication of Helicobacter pylori on the histology and cellular phenotype of gastric intestinal metaplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective | 2008 |
Extraintestinal heterotopic gastric tissue simulating acute appendicitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Acute Disease; Aged; Appendicitis; Choristo | 2008 |
[Helicobacter heilmannii: new spiral shaped bacterium that may be responsible for ulcerated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Amoxicillin; Anti-Ulcer Agents; Drug Therapy | 1995 |
Helicobacter pylori and lanzoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Helicobacter | 1996 |
Atopic dermatitis successfully treated by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Blott | 1996 |
[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1996 |
[Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Bacterial Agents; Clarithromycin | 1997 |
Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Female; Gastric Mucosa; Gastrins; Gastritis; H | 1997 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarke | 1997 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1997 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resist | 1996 |
Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cell Division; Epithelial C | 1997 |
Synergic interactions of macrolides and proton-pump inhibitors against Helicobacter pylori: a comparative in-vitro study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Dru | 1998 |
Effect of Helicobacter pylori infection on gastric juice pH.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Amoxicillin; Anti-Ulcer Agents; Case-Control Studi | 1998 |
Enhanced levels of C-X-C chemokine, human GROalpha, in Helicobacter pylori-associated gastric disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Chem | 1998 |
Iron-deficiency anemia associated with Helicobacter pylori gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anemia, Iron-Deficiency; Anti-Bacterial Agents; | 2000 |
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Enterochromaffin-like Cells; Enzyme Inhibitors; Fema | 2001 |
Regression of primary lymphoma of the ampulla of Vater after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Ampulla of Vater; Biopsy; Clarithromycin; Comm | 2001 |
[The effectiveness of 7-day combined Helicobacter eradication therapy in patients with peptic ulcer and chronic gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chronic Disease | 2001 |
Helicobacter pylori eradication in functional dyspepsia: new evidence for symptomatic benefit.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chronic Disease; Dyspepsia; Gastritis; Helicobacter Infecti | 2001 |